Compare FIX & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIX | TAK |
|---|---|---|
| Founded | 1917 | 1781 |
| Country | United States | Japan |
| Employees | N/A | 47455 |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.9B | 52.4B |
| IPO Year | 1997 | N/A |
| Metric | FIX | TAK |
|---|---|---|
| Price | $1,942.43 | $15.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $1,798.60 | N/A |
| AVG Volume (30 Days) | 351.2K | ★ 2.9M |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | 0.19% | ★ 3.24% |
| EPS Growth | ★ 97.81 | N/A |
| EPS | ★ 10.51 | N/A |
| Revenue | ★ $9,101,641,000.00 | N/A |
| Revenue This Year | $21.43 | $0.16 |
| Revenue Next Year | $13.14 | $1.22 |
| P/E Ratio | $182.73 | ★ $41.25 |
| Revenue Growth | ★ 29.52 | N/A |
| 52 Week Low | $489.98 | $12.99 |
| 52 Week High | $2,073.99 | $18.90 |
| Indicator | FIX | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 56.58 | 36.14 |
| Support Level | $1,736.87 | $14.84 |
| Resistance Level | $2,023.33 | $16.48 |
| Average True Range (ATR) | 99.20 | 0.21 |
| MACD | 4.48 | 0.04 |
| Stochastic Oscillator | 80.12 | 44.31 |
Comfort Systems USA Inc provides comprehensive mechanical contracting services, including heating, ventilation, & air conditioning, or HVAC; plumbing; piping & controls; construction; and other electrical components. Projects are mainly for commercial, industrial, & institutional buildings, & tend to be geared toward HVAC. Revenue is roughly split between installation services for newly constructed facilities & maintenance services for existing buildings. The company installs & repairs products and systems throughout the United States. It operates in two segments, Mechanical services & Electrical services, the majority is from the Mechanical services segment.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.